Welcome to our dedicated page for GSK PLC SEC filings (Ticker: GSK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
From breakthrough shingles vaccines to ViiV Healthcare’s HIV therapies, GSK’s science generates disclosures as complex as its pipeline. If you have ever wondered where the RSV launch costs are buried or how respiratory revenues move the needle, this page brings every document together and answers the questions people actually ask, like “GSK SEC filings explained simply” and “GSK insider trading Form 4 transactions.”
Stock Titan applies AI reading models to each new 20-F, 6-K, or proxy so you can skim instead of sift. Need the GSK quarterly earnings report 10-Q filing or an 8-K material events explained summary? You’ll see real-time alerts, plain-English highlights of vaccine safety data, and side-by-side comparisons of R&D spending. Our platform flags GSK Form 4 insider transactions real-time, traces option grants in the GSK proxy statement executive compensation section, and links each note to the relevant page in the PDF.
Whether you’re tracking patent-cliff timing, modelling Shingrix margins, or verifying GSK executive stock transactions Form 4, you’ll find everything here:
- Annual report 10-K simplified views (alongside the official 20-F)
- AI context for 6-K interim results and GSK earnings report filing analysis
- Instant download of exhibits that disclose trial halts, divestitures, or supply agreements
GSK plc announced that, acting through Merrill Lynch International, it purchased 207,767 ordinary shares on 09 September 2025 at an average price of 1,483.93p per share as part of its ongoing buyback programme.
The purchased shares will be held as Treasury shares. Since the non-discretionary broker agreement dated 4 June 2025, the Company has acquired 28,019,060 ordinary shares in total. After this transaction GSK will hold 246,153,443 ordinary shares in treasury and will have 4,069,248,284 ordinary shares in issue (excluding Treasury shares). The total number of voting rights is 4,069,248,284 and the percentage of voting rights attributable to treasury shares is 6.05%.
GSK plc reported an on-market purchase of 219,116 ordinary shares on 08 September 2025, executed by Merrill Lynch International under the non-discretionary buyback agreement announced 4 June 2025. The shares were bought at prices ranging around 1,460.93p to 1,485.50p per share and will be held as Treasury shares. Since 4 June 2025 the Company has purchased 27,811,293 ordinary shares under the same programme. After this transaction GSK will hold 245,945,676 ordinary shares in treasury and have 4,069,456,051 ordinary shares in issue (excluding Treasury shares), giving a total number of voting rights of 4,069,456,051. The Company states Treasury shares represent 6.04% of voting rights following the purchase.
GSK plc reported a transaction in own shares under its existing buyback programme. On 05 September 2025 the company, acting through Merrill Lynch International, purchased 276,710 ordinary shares at an average price of 1,472.87 pence per share. Since entering the non-discretionary agreement on 4 June 2025 the Company has purchased 27,592,177 ordinary shares. After this purchase GSK will hold 245,726,560 ordinary shares in treasury and will have 4,069,675,167 ordinary shares in issue excluding treasury shares, giving a total number of voting rights of 4,069,675,167. The Company reports that ordinary shares held in treasury represent 6.04% of voting rights following the purchase. Detailed individual trade prices and transaction references for the purchases on 05 September 2025 are provided in the filing.
GSK plc reports that on 04 September 2025 it repurchased 284,800 ordinary shares at an average price of 1,464.66p per share through Merrill Lynch International under its announced buyback programme. The purchased shares will be held as Treasury shares. Since the programme began on 4 June 2025, GSK has bought 27,315,467 ordinary shares. After this transaction the company holds 245,449,850 shares in treasury and has 4,069,946,246 ordinary shares in issue (excluding treasury), giving total voting rights of 4,069,946,246 and treasury-held voting rights of 6.03%.
GSK plc filed a Form 6-K reporting a transaction notification dated September 04, 2025. The filing identifies the security by ISIN GB00BN7SWP63 and discloses an aggregated volume of 10,050 shares. The document provides the transaction date and quantity but does not state the transaction price, the identity of the reporting person or counterparty, or aggregated price information.
GSK plc reports a routine purchase of its ordinary shares under an existing buyback programme. On 03 September 2025 the Company, through Merrill Lynch International, purchased 232,912 ordinary shares at prices in the range shown in the schedule and will hold the purchased shares as Treasury shares. Since the non-discretionary agreement dated 4 June 2025, the Company has purchased 27,030,667 ordinary shares. After this trade the Company holds 245,165,050 ordinary shares in treasury and has 4,070,231,046 ordinary shares in issue (excluding treasury); total voting rights are 4,070,231,046 and the percentage of voting rights attributable to treasury shares is 6.02%.
GSK plc announced that, acting through Merrill Lynch International, it purchased 296,202 ordinary shares of 31 3/4 pence each on 02 September 2025 at prices between 1,440.50p and 1,469.00p. The purchased shares will be held as treasury stock and form part of the company’s existing buyback programme under a non-discretionary agreement with the broker signed 4 June 2025. Since 4 June 2025 the company has bought 26,797,755 ordinary shares. After this transaction GSK will hold 244,932,138 shares in treasury, have 4,070,463,958 ordinary shares in issue excluding treasury shares, and a total number of voting rights of 4,070,463,958. The company reports that treasury shares represent 6.02% of voting rights following the purchase.
GSK plc reported a transaction in own shares under its announced buyback programme. Acting through Merrill Lynch International on 01 September 2025 the Company purchased 227,465 ordinary shares at prices between 1,442.00p and 1,468.50p per share; the aggregated lowest and highest reported prices on the day were 1,451.50p and 1,468.50p respectively. The purchased shares will be held as treasury shares and form part of the non-discretionary agreement with the Broker entered into on 4 June 2025. Since 4 June 2025 the Company has purchased 26,501,553 ordinary shares. Following this purchase the Company will hold 244,635,936 shares in treasury, have 4,070,760,160 ordinary shares in issue (excluding treasury) and treasury shares represent 6.01% of voting rights.
GSK plc reports its issued share capital and total voting rights as of 31 August 2025. The company had 4,315,396,096 Ordinary Shares of 31 pence each, of which 244,408,471 were held in Treasury, leaving a total of 4,070,987,625 voting rights. Shareholders may use this figure as the denominator to determine whether they must notify changes in their holdings under the FCA Disclosure Guidance and Transparency Rules.
GSK plc announced a purchase of 252,588 ordinary shares on 29 August 2025 as part of its ongoing buyback programme executed by Merrill Lynch International. The filing lists a lowest price of 1,447.00p, a highest price of 1,461.50p and an average price of 1,454.14p for that trading day. Since the non-discretionary agreement began on 4 June 2025 the Company has purchased 26,274,088 ordinary shares. Following this transaction GSK will hold 244,408,471 shares in treasury, have 4,070,987,625 ordinary shares in issue (excluding treasury) and total voting rights of 4,070,987,625. The filing also states treasury shares represent 6.00% of voting rights following the purchase.
FAQ
What is the current stock price of GSK PLC (GSK)?
What is the market cap of GSK PLC (GSK)?
